EUVIMEDEUVIMED entdecken
Open Access

Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli ‐Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real‐World Study in Chinese Girls

Tianmeng Wen, Li Dong, Jiayi Li, Yushu Feng, Lingling Nie, Zhongliang Li, Li Zhang, Shangying Hu, Weijin Huang, Fanghui Zhao iD, Partha Basu iD

International Journal of Cancer · 15.10.2026 · 159 (8) · 1904-1916

DOI: 10.1002/ijc.70553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 20.05.2026. Verfasst von Tianmeng Wen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences …. Hauptthemen laut MEDLINE: Antibodies, Viral, Human papillomavirus 16, Human papillomavirus 18, Immunologic Memory. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, Science and Technology Partnership Program, Ministry of Science and Technology of China, Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A comprehensive profile of immunogenicity induced by a single dose of human papillomavirus (HPV) vaccination has yet to be presented. We report interim data from an ongoing non‐interventional real‐world study comparing the memory cell and antibody responses following single‐ and two‐dose regimens of the Escherichia coli ‐produced HPV‐16/18 vaccine in Chinese girls aged 9–14 years. HPV‐16/18‐specific neutralizing antibodies, IgG antibodies, and memory B‐ and T‐cell responses were assessed and compared between the single‐dose and two‐dose groups. The results showed that among 492 per‐protocol participants (298 two‐dose; 194 single‐dose), the median time from Dose 1 to blood sampling was 12.07 months. Single‐dose neutralizing antibody seropositivity exceeded 90% for HPV‐16 and approached 80% for HPV‐18. The antibody avidity index of HPV‐16 IgG after a single dose was non‐inferior to that after two doses (lower bound of the geometric mean avidity ratio > 0.5). Both dosing schedules induced HPV‐16/18‐specific memory B‐ and T‐cell responses with similar positivity and geometric means ( p > 0.05). Therefore, a single dose of the E. coli ‐produced HPV‐16/18 vaccine elicited robust antibody quantity and quality, with memory B‐ and T‐cell responses comparable to those induced by two doses, supporting its potential for population‐level implementation and contribution to the WHO target of vaccinating 90% of girls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralHuman papillomavirus 16Human papillomavirus 18Immunologic MemoryPapillomavirus InfectionsPapillomavirus VaccinesAdolescentChildFemaleHumansAntibodies, NeutralizingAntibody FormationB-LymphocytesChinaEscherichia coliImmunoglobulin GT-Lymphocytes

Stichwörter der Autor:innen

Escherichia coli‐produced human papillomavirus vaccinesantibody avidityantibody titersmemory B cellssingle dose

Substanzen

Antibodies, NeutralizingAntibodies, ViralImmunoglobulin GPapillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Institute of Biomedical Sciences, Shanxi University, Taiyuan, China.
  • National Institutes for Food and Drug Control (NIFDC), Beijing, China.
  • Early Detection, Prevention & Infections Branch, International Agency for Research on Cancer, Lyon, France.

ORCID-Profile: Fanghui Zhao, Partha Basu

Förderung

  • World Health Organization
  • Science and Technology Partnership Program, Ministry of Science and Technology of China
  • Gates Foundation
  • National Natural Science Foundation of China
  • Bill and Melinda Gates Foundation

Zitieren

APA

Wen, T., Dong, L., Li, J., Feng, Y., Nie, L., Li, Z., Zhang, L., Hu, S., Huang, W., Zhao, F., & Basu, P. (2026). Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli ‐Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real‐World Study in Chinese Girls. International Journal of Cancer, 159(8), 1904-1916. https://doi.org/10.1002/ijc.70553

Vancouver

Wen T, Dong L, Li J, Feng Y, Nie L, Li Z, et al. Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli ‐Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real‐World Study in Chinese Girls. International Journal of Cancer. 2026;159(8):1904-1916. doi:10.1002/ijc.70553

BibTeX
@article{Wen2026,
  author = {Wen, Tianmeng and Dong, Li and Li, Jiayi and Feng, Yushu and Nie, Lingling and Li, Zhongliang and Zhang, Li and Hu, Shangying and Huang, Weijin and Zhao, Fanghui and Basu, Partha},
  title = {Memory Cell and Antibody Responses Following a Single Versus Two Doses of Escherichia coli ‐Produced Vaccine Against Human Papillomavirus Types 16 and 18: A Real‐World Study in Chinese Girls},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {1904--1916},
  doi = {10.1002/ijc.70553}
}
Kostenlos starten →